Royalty Report: Diagnostic, Medical, Device – Collection: 5650

License Grant

Licensor grants to Licensee and its Affiliates a limited non-exclusive, personal and non-transferable, right and subLicense under the Licensed Patents, to make, have made for its own use and sale, use, offer to sell, sell and import product within the field and within the territory, and to practice the methods claimed in the Licensed Patents in connection with such product, and to extend to its customers purchasing product the right to use and sell the product purchased and to practice the methods claimed in the Licensed Patents in connection with such product.

License Property

Licensed Patent shall mean United States Patent Nos. 5,073,484, 5,654,162 and 6,020,147 and any patents resulting from a re-examination or reissue from any of the foregoing patents.

The patents are for a device for detecting the presence of an analyte in a carrier liquid suspected of containing said analyte, which device comprises a liquid permeable solid medium which defines a path for fluid flow capable of supporting capillary flow, along which are a site for application of the carrier liquid, a diffusively bound labeled reactant specific for the analyte or a chemical moiety which is itself the reaction product of the analyte with another chemical moiety, said labeled reactant being capable of flow along the flow path, wherein said diffusively bound labeled reactant and said analyte or chemical moiety are of a specific ligand-anti ligand pair, and one or more zones spaced along said flow path, each zone having a predetermined amount of a reactant bound to it which is specific for either the analyte or a chemical moiety which is itself the reaction product of the analyte with another chemical moiety.

Wherein said device can be used by contacting a carrier liquid with said application site in such a manner that permits said liquid to pass along the flow path by capillary flow such that analyte or reaction product of the analyte with another chemical moiety becomes bound to both the labeled reactant and the reactant bound to the solid medium;  and wherein the labeled reactant, with the reactant bound to the solid medium, sandwiches the analyte or a chemical moiety which is itself the reaction product of the analyte with another chemical moiety.

Lateral flow tests also known as lateral flow immunochromatographic assays, are simple devices intended to detect the presence (or absence) of a target analyte in sample (matrix) without the need for specialized and costly equipment, though many lab based applications exist that are supported by reading equipment.[2] Typically, these tests are used for medical diagnostics either for home testing, point of care testing, or laboratory use.

License Grant

Licensor hereby grants a non-exclusive, non-transferable, right and sublicense under the Licensed Patents, to make, have made for its own use and sale, use, offer to sell, sell and import product within the field.

License Property

A method and apparatus for the quantitative determination of an analyte in a liquid employs a liquid-permeable solid medium defining a liquid flow path.  The medium includes a number of reaction-containing reaction zones spaced apart along the flow path and in which reaction occurs with the analyte or an analyte derivative (e.g., a labeled analyte) to result in the formation of a predetermined product.  Detector means are employed to detect analyte, analyte derivatives, reactant or predetermined product in the reaction zones, the number of such zones in which such detection occurs indicating the amount of analyte in the liquid.

Licensed Patents shall mean United States Patent
5,073,484,  5,654,162 and 6,020,147

Field of Use

Field shall mean human in vitro diagnostics.

License Grant

Licensor grants to a worldwide, nonexclusive, nontransferable right and license, with no right to grant any sublicenses, to make, have made, use, and sell Licensed products. Accordingly, the license includes the right of Licensee and purchasers of its Licensed products to practice methods covered by the Licensed patents and Licensed patent applications only by using such licensed products.

License Property

Licensor owns all rights to United States Patent titled Heterogenous chemiluminescent specific binding assay, and, its corresponding foreign-filed counterparts covering certain chemiluminescent specific binding assay methods and reagent systems.

Licensed Product shall mean a product for performing a Chemilumniescent Immunoassay only, and no other product, which when made, used, or sold would infringe a claim of a Licensed patent.

Chemilumniescent Immunoassay shall mean a liquid-phase heterogeneous chemiluminescent assay employing a chemiluminescent reactant as label and wherein the substance or condition to be determined, i.e., analyte of interest, is determined by binding thereto of an antibody or other specific binding protein.

Field of Use

Licensee intends to develop and market instruments and reagent systems for performing chemiluminescent immunoassays.

License Grant

The Licensor of England grants to the Licensee a non-exclusive license under the Patent Rights in the Territory to make, use and sell Licensed Products.

Licensor grants to the Licensee a non-exclusive option to a license to make, use and sell Products Under Option. This option may be exercised on a per analyte basis at any time within the two (2) year period subsequent to the Effective Date of the Agreement, whereupon it will cease on a per analyte basis.

License Property

Licensed Product shall mean any device for qualitative or quantitative detection of the analytes Fetal Fibronectin, and, Interleukin 6 for Group B Strep and Chlamydia.

Products Under Option shall mean any device for qualitative or quantitative detection of the analytes Fetal Fibronectin, and, Interleukin 6 for Group B Strep and Chlamydia.

Fetal fibronectin (fFN) is a fibronectin protein produced by fetal cells. It is found at the interface of the chorion and the decidua (between the fetal sac and the uterine lining). It can be thought of as an adhesive or 'biological glue' that binds the fetal sac to the uterine lining.

Field of Use

Fetal fibronectin (fFN) is used to test pregnant women who are between 22 weeks and 35 weeks of gestation and are having symptoms of premature labor. The test helps predict the likelihood of premature delivery. Many pregnant women experience symptoms that suggest preterm labor.

Licensee designs, develops, manufactures and markets innovative products for women’s health, with focus on reproductive healthcare, using proprietary technologies to predict preterm birth and assess infertility.